BR112014022687A8 - uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo - Google Patents

uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo

Info

Publication number
BR112014022687A8
BR112014022687A8 BR112014022687A BR112014022687A BR112014022687A8 BR 112014022687 A8 BR112014022687 A8 BR 112014022687A8 BR 112014022687 A BR112014022687 A BR 112014022687A BR 112014022687 A BR112014022687 A BR 112014022687A BR 112014022687 A8 BR112014022687 A8 BR 112014022687A8
Authority
BR
Brazil
Prior art keywords
ester
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
effective amount
Prior art date
Application number
BR112014022687A
Other languages
English (en)
Other versions
BR112014022687A2 (pt
Inventor
Deepak Phadke
Curt D Wolfgang
Mihael H Polymeropoulos
John Joseph Feeney
Gunther Birznieks
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014022687(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of BR112014022687A2 publication Critical patent/BR112014022687A2/pt
Publication of BR112014022687A8 publication Critical patent/BR112014022687A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo. r-p88 é usado para o tratamento de distúrbios sensíveis ao tratamento com um antipsicótico atípico.
BR112014022687A 2012-03-14 2013-03-14 uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo BR112014022687A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610664P 2012-03-14 2012-03-14
PCT/US2013/031413 WO2013138602A1 (en) 2012-03-14 2013-03-14 An iloperidone metabolite for use in the treatment of psychiatric disorders

Publications (2)

Publication Number Publication Date
BR112014022687A2 BR112014022687A2 (pt) 2017-06-20
BR112014022687A8 true BR112014022687A8 (pt) 2021-07-06

Family

ID=48407766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014022687A BR112014022687A8 (pt) 2012-03-14 2013-03-14 uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo

Country Status (17)

Country Link
US (3) US10874659B2 (pt)
EP (2) EP2825167B1 (pt)
JP (5) JP2015510893A (pt)
KR (2) KR20170008327A (pt)
CN (2) CN104203240A (pt)
AU (2) AU2013232014B2 (pt)
BR (1) BR112014022687A8 (pt)
CA (1) CA2865845C (pt)
CL (1) CL2014002430A1 (pt)
CO (1) CO7091183A2 (pt)
ES (2) ES2677474T3 (pt)
IL (1) IL234412B (pt)
IN (1) IN2014DN08495A (pt)
MX (1) MX2014010989A (pt)
RU (1) RU2651710C2 (pt)
WO (1) WO2013138602A1 (pt)
ZA (1) ZA201406369B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017017608A2 (pt) 2015-02-17 2018-05-08 Vanda Pharmaceuticals Inc métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
DK1425272T3 (da) 2001-08-31 2011-11-21 Novartis Ag Optiske isomerer af en iloperidon-metabolit
CA2468972A1 (en) 2001-12-10 2003-07-03 Novartis Ag Methods of treating psychosis and schizophrenia based on a polymorphism in the cntf gene
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
CA2582022C (en) 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
AU2007253684A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
ES2542967T3 (es) 2007-03-29 2015-08-13 Vanda Pharmaceuticals Inc. Método de predecir una predisposición a la prolongación de QT
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
EP2198049A1 (en) 2007-09-10 2010-06-23 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on snp genotype
WO2010117931A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP5692872B2 (ja) 2009-04-06 2015-04-01 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｂａｉ遺伝子の配列又はその産物に基づいてｑｔ延長に対する素因を予測する方法
US9074256B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
EP2417266B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US9057104B2 (en) 2009-05-15 2015-06-16 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype

Also Published As

Publication number Publication date
IL234412B (en) 2018-04-30
IN2014DN08495A (pt) 2015-05-08
US20210015809A1 (en) 2021-01-21
US20150045390A1 (en) 2015-02-12
EP3345603A1 (en) 2018-07-11
US10874659B2 (en) 2020-12-29
AU2013232014A1 (en) 2014-09-18
AU2016203591A1 (en) 2016-06-16
CA2865845C (en) 2020-02-18
EP2825167A1 (en) 2015-01-21
JP2017061506A (ja) 2017-03-30
JP7151029B2 (ja) 2022-10-12
ES2773711T3 (es) 2020-07-14
CL2014002430A1 (es) 2015-04-17
BR112014022687A2 (pt) 2017-06-20
EP2825167B1 (en) 2018-05-09
WO2013138602A1 (en) 2013-09-19
JP2018203774A (ja) 2018-12-27
JP2015510893A (ja) 2015-04-13
CO7091183A2 (es) 2014-10-21
KR20140121487A (ko) 2014-10-15
KR20170008327A (ko) 2017-01-23
JP2021001221A (ja) 2021-01-07
AU2016203591B2 (en) 2018-03-08
EP3345603B1 (en) 2019-12-18
JP2023022243A (ja) 2023-02-14
ES2677474T3 (es) 2018-08-02
MX2014010989A (es) 2015-03-10
ZA201406369B (en) 2023-10-25
CN104203240A (zh) 2014-12-10
RU2014141112A (ru) 2016-05-10
AU2013232014B2 (en) 2016-06-16
RU2651710C2 (ru) 2018-04-23
US20240016791A1 (en) 2024-01-18
CA2865845A1 (en) 2013-09-19
CN108938632A (zh) 2018-12-07

Similar Documents

Publication Publication Date Title
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
EA201790785A1 (ru) Производные тетрагидроизохинолина
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015004499A2 (pt) métodos de administração de terapia de pirfenidona
BR302012004627S1 (pt) "padrão aplicado a interface gráfica de usuário para uma tela de exibição ou parte da mesma"
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
CL2015002606A1 (es) Compuesto.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
ECSP13012460A (es) 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3
BR112014022687A8 (pt) uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]